别名 SPTCL、Subcutaneous Panniculitis-Like T-Cell Lymphoma、Subcutaneous Panniculitis-Like T-Cell Lymphoma (Alpha/Beta Type) + [10] |
简介 A cytotoxic primary cutaneous T-cell lymphoma. Recent studies suggest there are at least two groups of subcutaneous panniculitis-like T-cell lymphomas, each with distinct histologic features, immunophenotypic profile, and prognosis. One group has an alpha/beta, CD8 positive phenotype, involves only subcutaneous tissues, and usually has an indolent clinical course. The second group has a gamma/delta phenotype, is CD8 negative, often co-expresses CD56, is not confined to the subcutaneous tissues, and usually has a poor prognosis. In the recent WHO-EORTC classification, the term subcutaneous panniculitis-like T-cell lymphoma is reserved for cases with an alpha/beta, CD8 positive phenotype. Cases with a gamma/delta phenotype are included in the group of cutaneous gamma/delta T-cell lymphomas. |
靶点 |
作用机制 PD-1抑制剂 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2014-09-04 |
作用机制 CK1α抑制剂 [+3] |
在研机构 |
原研机构 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2005-12-27 |
靶点 |
作用机制 CD20抑制剂 [+3] |
原研机构 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期1997-11-26 |
开始日期2024-07-17 |
开始日期2024-05-27 |
申办/合作机构- |
开始日期2023-07-27 |